Treatment goals of blood lipids in high risk patients of atherosclerotic disease;Behandlingsmål for blodlipider hos høyrisikopasienter for aterosklerotisk sykdom

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 9, 2001, Pages 1059-1063

  Svilaas, Arne ^a   Ose, Leiv ^a   Risberg, Knut ^b   Thoresen, Magne ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Vestvollen Legesenter   (Norway)

^c Seksjon for Medisinsk Statistikk   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; DOSE RESPONSE; GENERAL PRACTITIONER; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NORWAY; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK FACTOR; SECONDARY PREVENTION;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; RISK FACTORS; TRIGLYCERIDES;

EID: 14344284404     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Scandinavian Simvastatin Survival Study Group: randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Sacks FM, Pfeffer MA, Move LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after acute myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
3. Shepherd J, Cobbe SM, Lorimer AR, McKillop JU, Ford I, Packard CJ et al. for the West of Scotland Coronary Prevention Study Group. West of Scotland Coronary Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42.
4. Pyörälä K, Pedersen T, Kjekshus, J, Færgeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary disease. The Scandinavian Simvastatin Survival Study (4S) Group. Diabetes Care 1997; 20: 614-20.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
6. Wood D, De Backer G, Færgeman O, Graham I, Mancia G, Pyörälä K together with members of the task force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.
7. Statens legemiddelkontroll. Terapianbefaling: Behandling av hyperlipidemi. SLK-publikasjon 2000: 06. www.slk.no/terapi/publiserte_terapi. htm (7.6. 2000).
8. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-62.
9. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA et al. and Post CABG investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft trial. Circulation 2000; 102: 157-65.
10. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
11. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-7.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
13. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemi (The CURVES Study). Am J Cardiol 1998; 81: 582-7.
14. Krone W, Schmage N, Breuer H-WM. Comparison of long-term efficacy and safety of cerivastatin versus pravastatin in primary hypercholesterolaemia. J Clin Research 1999; 2: 141-53.
15. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
16. Law M. Lipids and cardiovascular disease. I: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, red. Evidence based cardiology. London: BMJ Books, 1998: 191-205.
17. LaRosa JC, He J, Vupputuri S. Effects for statins on risk of coronary disease. JAMA 1999; 282: 2340-6.
18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
19. Svilaas A, Walsøe HK, Ose L. Lipid treatment goals in patients with atherosclerotic disease. Nutr Metab Cardiovasc Dis 2000; 10: 71-8.
20. Svilaas, A, Bergei CS, Strom EC, Ose L, Walsøe HK. Kostholdet hos pasienter med aterosklerotisk sykdom sammenliknet med befolkningen. Tidsskr Nor Lægeforen 2000; 120: 2618-24.
21. Svilaas A, Kristoffersen JE, Hjartaaker J, Westheim A. How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. Scand J Prim Health Care 2000; 18: 232-6.
22. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82: 61-5.
23. Gotto AM jr., Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-84.
24. Illingworth DR, Durrington PN. Dyslipidemia and atherosclerosis: How much more evidence do we need? Curr Opin Lipidol 1999; 10: 383-6.
25. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: clinical practice recommendations. Diabetes Care 1998; 21(suppl 1): 5-19.
26. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Levereux RB et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler Thromb Vase Biol 2000; 20: 830-5.
27. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JDG, Hunt D et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343: 317-26.
28. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med 2000; 160: 459-67.
29. Crouse JR, Frohlich J, Ose L, Mercuri M, Tobert JA. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1. Am J Cardiol 1999; 83: 1476-7.
30. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B-9.
31. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19 (suppl A): A31-5.
32. Rubbins HB, Collins D, Robins SJ. The VA HDL Intervention Trial: clinical implications. Eur Heart J 2000; 21: 1113-5.
33. Miller M. Giving triglycerides their due. Hosp Pract 1999; 34: 67-73.
34. Durrington PN, Illingworth DR. Lipidlowering drug therapy: more knowledge leads to more problems for composers of guidelines. Curr Opin Lipidol 2000; 11: 345-9.
35. Miller M, Vogel RA. The practice of coronary disease prevention. Baltimore, MD: Williams & Wilkins, 1996: 225-42.
36. Funke H, Assmann G. Strategies for the assessment of genetic coronary artery disease risk. Curr Opin Lipidol 1999; 10: 285-91.
37. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999; 341: 217-25.
38. Svilaas A, Ose L, Risberg K, Thoresen M. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 2000: 86: 1250-3.